Fully Synthetic, Nature-Inspired Exosome-Mimetics for Melanoma Therapy

dc.contributor.author Arda Ozturk N.Z.
dc.contributor.author Majchrzak O.B.
dc.contributor.author Ulivi G.
dc.contributor.author Kirmizibayrak P.B.
dc.contributor.author Borchard G.
dc.contributor.author Patrulea V.
dc.contributor.author Ozer O.
dc.contributor.author Ozturk, Nahide Zeren Arda
dc.contributor.author Borchard, Gerrit
dc.contributor.author Ozer, Ozgen
dc.contributor.author Patrulea, Viorica
dc.contributor.author Majchrzak, Oliwia Barbara
dc.contributor.author Arda Ozturk, Nahide Zeren
dc.contributor.author Kirmizibayrak, Petek Ballar
dc.contributor.author Ulivi, Gianluca
dc.date.accessioned 2026-03-12T14:36:08Z
dc.date.available 2026-03-12T14:36:08Z
dc.date.issued 2026
dc.description.abstract Fully synthetic exosome-mimetics (FSEMs) represent a nature-inspired drug delivery system designed to replicate the key physicochemical and biological properties of natural exosomes, while offering the potential to address limitations in scalability and reproducibility associated with natural exosomes. In this study, we prepared FSEMs at the laboratory scale. We loaded them with (–)-epigallocatechin-3-gallate (EGCG) and microRNA-23a (miR-23a), aiming to co-deliver therapeutic small molecules and nucleic acids for the treatment of melanoma. FSEMs were fabricated using three methods: thin-film hydration, ethanol injection, and microfluidics. They were surface-functionalized with either CD9, a tetraspanin involved in membrane fusion, or TSP-1, an adhesion protein promoting cellular interactions. Through physicochemical characterization via dynamic light scattering, we found that FSEMs were ∼ 100 nm in size, of low polydispersity (∼0.2) and showed a negative zeta potential (∼–55 mV). Both EGCG and miR-23a were efficiently encapsulated. SDS-PAGE analysis confirmed successful protein incorporation and correct positioning. In vitro release studies showed minimal premature leakage, supporting their suitability for cellular uptake-mediated delivery. When tested on melanoma cells (MDA-MB-435) and progenitor human dermal fibroblasts (FE002-SK2), FSEMs selectively killed melanoma cells while sparing fibroblasts. Importantly, EGCG within FSEMs was more effective than the free compound. Compared to conventional DOTAP-based liposomes, FSEMs were more selective and induced less off-target cytotoxicity. This study presents a proof-of-concept for fully synthetic, protein-functionalized FSEMs as dual carriers for both chemical and gene-based agents, offering a safer and potentially more effective alternative to traditional cationic liposomes. These results lay the groundwork for future in vivo validation and translational cancer research. © 2026 The Author(s) en_US
dc.description.sponsorship This article is part of the doctoral research of Prof Nahide Zeren Arda Ozturk, conducted at Ege University, Turkiye. Prof Nahide Zeren Arda Ozturk received support from the TUBITAK 2214/A International Research Fellowship Programme (Project No. 1059B142201060) during her research stay at the University of Geneva, Switzerland. The financial and institutional support provided by the Ege University Office of Scientific Research Projects (Project No. 23840) and the TUBITAK 2244 Industrial PhD Fellowship Programme (Project No. 119C113) is gratefully acknowledged. Additional support from the Council of Higher Education through the 100/2000 scholarship programme is also sincerely appreciated. The authors extend their sincere gratitude to Abdi Ibrahim Pharmaceuticals for donating raw materials and serving as an industrial advisory partner within the TUBITAK 2244 programme.We also acknowledge Dr Claudia Simoes Avello and Mr Gael Vieille (University of Geneva) for assistance with the Qubit assay, Mrs Emmanuelle Sublet (University of Geneva) for support with cell culture, and Mr Tayeb Jbilou (University of Geneva) for assistance with TEM and SEM analyses.
dc.description.sponsorship This article is part of the doctoral research of Prof Nahide Zeren Arda Oztürk, conducted at Ege University , Turkiye. Prof Nahide Zeren Arda Oztürk received support from the TUBITAK 2214/A International Research Fellowship Programme (Project No. 1059B142201060 ) during her research stay at the University of Geneva , Switzerland. The financial and institutional support provided by the Ege University Office of Scientific Research Projects (Project No. 23840) and the TUBITAK 2244 Industrial PhD Fellowship Programme (Project No. 119C113 ) is gratefully acknowledged. Additional support from the Council of Higher Education through the 100/2000 scholarship programme is also sincerely appreciated. The authors extend their sincere gratitude to Abdi Ibrahim Pharmaceuticals for donating raw materials and serving as an industrial advisory partner within the TUBITAK 2244 programme.
dc.description.sponsorship Yükseköğretim Kurulu; Université de Genève, UNIGE; A International Research, (1059B142201060); Ege Üniversitesi, (23840); Ege Üniversitesi; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, TUBITAK, (119C113); Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, TUBITAK
dc.description.sponsorship TUBITAK 2214/A International Research Fellowship Programme [1059B142201060]; Ege University Office of Scientific Research Projects [23840]; TUBITAK 2244 Industrial PhD Fellowship Programme [119C113]; Council of Higher Education through the 100/2000 scholarship programme
dc.identifier.doi 10.1016/j.ijpharm.2026.126715
dc.identifier.issn 0378-5173
dc.identifier.issn 1873-3476
dc.identifier.scopus 2-s2.0-105031584374
dc.identifier.uri https://doi.org/10.1016/j.ijpharm.2026.126715
dc.identifier.uri https://hdl.handle.net/20.500.14627/1461
dc.language.iso en en_US
dc.publisher Elsevier B.V. en_US
dc.relation.ispartof International Journal of Pharmaceutics en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject (-)-Epigallocatechin-3-Gallate (EGCG) en_US
dc.subject Fully Synthetic Exosome-Mimetics (FSEMs) en_US
dc.subject Microfluidics en_US
dc.subject Microrna-23A (miR-23A) en_US
dc.subject Nanotechnology en_US
dc.subject Vesicular Drug Delivery Systems en_US
dc.subject (–)-Epigallocatechin-3-Gallate (EGCG)
dc.title Fully Synthetic, Nature-Inspired Exosome-Mimetics for Melanoma Therapy en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Arda Ozturk, Nahide Zeren/0000-0001-9440-4230
gdc.author.scopusid 59457870900
gdc.author.scopusid 37029774600
gdc.author.scopusid 60430197500
gdc.author.scopusid 57222366085
gdc.author.scopusid 7004023476
gdc.author.scopusid 55601807000
gdc.author.scopusid 55601807000
gdc.author.scopusid 7003918121
gdc.author.wosid Patrulea, Viorica/P-4334-2019
gdc.author.wosid Arda, Zeren/KYQ-9206-2024
gdc.author.wosid Ballar Kirmizibayrak, Petek/Y-6869-2018
gdc.author.wosid ÖZER, Kevser/KBA-5695-2024
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.description.department Fenerbahçe University en_US
gdc.description.departmenttemp [Arda Ozturk N.Z.] Fenerbahce University, Faculty of Pharmacy, Pharmaceutical Technology Department, Istanbul, Turkey, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, Ege University, Faculty of Pharmacy, Pharmaceutical Technology Department, Izmir, Turkey; [Majchrzak O.B.] Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland; [Ulivi G.] Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland; [Kirmizibayrak P.B.] Ege University, Faculty of Pharmacy, Biochemistry Department, Izmir, Turkey; [Borchard G.] Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland; [Patrulea V.] Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland, School of Pharmaceutical Sciences, University of Geneva, 1 Rue Michel Servet, Geneva, 1211, Switzerland; [Ozer O.] Ege University, Faculty of Pharmacy, Pharmaceutical Technology Department, Izmir, Turkey en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality N/A
gdc.description.volume 693 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q1
gdc.identifier.openalex W7131345978
gdc.identifier.pmid 41759643
gdc.identifier.wos WOS:001709051000001
gdc.index.type Scopus
gdc.index.type PubMed
gdc.index.type WoS
gdc.openalex.fwci 0.0
gdc.openalex.normalizedpercentile 0.73
gdc.plumx.scopuscites 0
gdc.scopus.citedcount 0

Files